Rockefeller Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Rockefeller Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.35M	Hold	173,438	–	–	0.01%	739
2025 Q4	$7.15M	Hold	173,438	–	–	0.01%	769
2025 Q3	$6.73M	Buy	+173,438	New	+$5.63M	0.01%	743
2023 Q1	–	Sell	-5,750	Closed	-$86K	–	3009
2022 Q4	$86K	Hold	5,750	–	–	﹤0.01%	2102
2022 Q3	$73K	Hold	5,750	–	–	﹤0.01%	2162
2022 Q2	$55K	Hold	5,750	–	–	﹤0.01%	2233
2022 Q1	$57K	Hold	5,750	–	–	﹤0.01%	2239
2021 Q4	$67K	Buy	5,750 +5,000	+667%	+$61.4K	﹤0.01%	2087
2021 Q3	$8K	Hold	750	–	–	﹤0.01%	2995
2021 Q2	$10K	Hold	750	–	–	﹤0.01%	2776
2021 Q1	$13K	Hold	750	–	–	﹤0.01%	2481
2020 Q4	$13K	Hold	750	–	–	﹤0.01%	2154
2020 Q3	$11K	Hold	750	–	–	﹤0.01%	1987
2020 Q2	$19K	Buy	+750	New	+$15.7K	﹤0.01%	1694

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Rockefeller Capital Management's KNSA Position: Q1 2026 in Review

Rockefeller Capital Management held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 173,438 shares worth $8.35M. The position accounts for 0.01% of the portfolio, ranked #739.

Rockefeller Capital Management first reported a position in KNSA in Q2 2020 and has held it in 14 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Rockefeller Capital Management held 173,438 shares of Kiniksa Pharmaceuticals worth $8.35M as of Q1 2026.
Rockefeller Capital Management left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
Kiniksa Pharmaceuticals made up 0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #739 holding.
Rockefeller Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.